stockrowErasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Free cash flow margin
Erasca, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from 0.00% (fiscal 2025) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| TVTX Travere Therapeutics, Inc. compare | 13.1% |
| COGT Cogent Biosciences, Inc. compare | 0.00% |
| MANE Veradermics Incorporated compare | 0.00% |
| SRRK Scholar Rock Holding Corporation compare | 0.00% |
| ERAS Erasca, Inc. | 0.00% |
| PTCT PTC Therapeutics, Inc. compare | −22.4% |
| CRSP CRISPR Therapeutics AG compare | −1,496.6% |
| CGON CG Oncology, Inc. compare | −2,879.6% |
| DNTH Dianthus Therapeutics, Inc. compare | −6,469.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue